GSK's Zejula Poised To Take On Lynparza In First-Line Ovarian Cancer
The Phase III PRIMA study in first-line ovarian cancer was positive for progression-free survival in patients regardless of their biomarker status, GSK reported.
You may also be interested in...
Stay-at-home restrictions due to COVID-19 have started to impact the company's vaccines business, including the big growth driver Shingrix.
GSK looks to become a cancer contender once again, while Merck and Roche go toe-to-toe in TNBC.
US Pharmaceuticals President Jack Bailey will step down, to be succeeded by Maya Martinez-Davis, currently at Merck KGAA.